CD133: A marker of transit amplification rather than stem cell phenotype in the prostate?: Comments

BJU International

Volumn 103, Issue 7, 2009, Pages 856-858

  Grey, Benjamin R ^a,b   Oates, Jeremy E ^a   Brown, Michael D ^a   Clarke, Noel W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN;

CANCER STEM CELL; CELL PROLIFERATION; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; STEM CELL; STEM CELL EXPANSION;

ANTIGENS, CD; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; MALE; PEPTIDES; PHENOTYPE; PROSTATE; TUMOR MARKERS, BIOLOGICAL;

EID: 62149117868     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08250.x     Document Type: Note

References (17)

1. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000 100 : 157 68
2. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984 5 : 545 57
3. Huntly BJ, Shigematsu H, Deguchi K et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004 6 : 587 96
4. Krivtsov AV, Twomey D, Feng Z et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006 442 : 818 22
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001 414 : 105 11
6. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006 355 : 1253 61
7. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004 117 : 3539 45
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005 65 : 10946 51
9. van Leenders GJ, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int 2001 88 (Suppl. 2 35 42
10. Beier D, Hau P, Proescholdt M et al. CD133+ and CD133- Glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007 67 : 4010 5
11. Wang J, Sakariassen PO, Tsinkalovsky O et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008 122 : 761 8
12. Florek M, Haase M, Marzesco AM et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005 319 : 15 26
13. Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008 118 : 2111 20
14. Oates JE, Grey BR, Swann R, Hart C, Brown MD, Clarke NW. CD133 is a marker for early proliferative cells but not cancer stem-cells in renal cell carcinoma. BJU Int 2008 101 (Suppl. 5 43
15. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996 183 : 1797 806
16. Bhatt RI, B rown MD, Hart CA et al. Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry A 2003 54A : 89 99
17. Brown MD, Gilmore PE, Hart CA et al. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 2007 67 : 1384 96